CIK: 0002003147
Total reported value
$364.5M
Reporting period: 2026-03-31 · Number of holdings: 17
Davern Capital Partners, LP disclosed 17 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $364.5M and a quarterly turnover rate of 40.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "D"
Davern Capital Partners, LP's disclosed holdings carry a Herfindahl concentration index of 0.075 — mathematically equivalent to about 13 equally-sized positions, close to its 17 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.54), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Trim PFE
-22.0% -$6.1M
Add LLY
+228.4% $16.2M
Trim BNTX
-17.8% -$8.2M
Trim RPRX
-38.1% -$7.5M
Trim REGN
-14.5% -$5.8M
Trim ARGX
-1.8% -$4.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer INC | Stock-Healthcare | 12.28% | -4.16% | -21.95% | |
| 2 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 9.50% | -3.58% | -14.54% | |
| 3 | INSM | Insmed INC | Stock-Healthcare | 8.19% | +8.19% | NEW | |
| 4 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 7.97% | +1.87% | +62.24% | |
| 5 | NTRA | Natera INC | Stock-Healthcare | 7.90% | +2.07% | +83.05% | |
| 6 | BNTX | Biontech Se-adr | Stock-Other | 7.44% | -3.99% | -17.82% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.02% | -2.68% | -1.79% | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.88% | +3.99% | +228.39% | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 6.84% | -3.66% | -38.14% | |
| 10 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.64% | -0.57% | -15.06% | |
| 11 | LEGN | Legend Biotech Corp-adr | Stock-Other | 6.52% | -0.91% | +24.42% | |
| 12 | MLYS | Mineralys Therapeutics INC | Stock-Other | 3.32% | +0.85% | +112.28% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.39% | +0.28% | +61.08% | |
| 14 | GENB | Generate Biomedicines INC | Stock-Other | 2.03% | +2.03% | NEW | |
| 15 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.79% | +1.79% | NEW | |
| 16 | GPCR | Structure Therapeutics INC | Stock-Other | 1.67% | +1.67% | NEW | |
| 17 | VRDN | Viridian Therapeutics INC | Stock-Other | 1.62% | -1.01% | +15.61% |
Performance for Q3 2026
+3%
Performance Last 4 Quarters
-2.1%
Based on 5 months of available history
Based on 70% of reported portfolio value with available pricing
Davern Capital Partners, LP's most significant position changes for 2026-03-31: New buy: Insmed INC (INSM); New buy: Generate Biomedicines INC (GENB); Sold out: Cg Oncology INC (CGON); New buy: Procept Biorobotics CORP (PRCT); New buy: Structure Therapeutics INC (GPCR).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +4% | +228.39% | Add |
| 2 | NTRA | Natera INC | +2.1% | +83.05% | Add |
| 3 | IONS | Ionis Pharmaceuticals INC | +1.9% | +62.24% | Add |
| 4 | MLYS | Mineralys Therapeutics INC | +0.9% | +112.28% | Add |
| 5 | ABVX | Abivax Sa-adr | +0.3% | +61.08% | Add |
| 6 | ROIV | Roivant Sciences Ltd. | -0.6% | -15.06% | Trim |
| 7 | LEGN | Legend Biotech Corp-adr | -0.9% | +24.42% | Add |
| 8 | VRDN | Viridian Therapeutics INC | -1% | +15.61% | Add |
| 9 | ARGX | Argenx Se - Adr | -2.7% | -1.79% | Trim |
| 10 | REGN | Regeneron Pharmaceuticals | -3.6% | -14.54% | Trim |
| 11 | RPRX | Royalty Pharma plc | -3.7% | -38.14% | Trim |
| 12 | BNTX | Biontech Se-adr | -4% | -17.82% | Trim |
| 13 | PFE | Pfizer INC | -4.2% | -21.95% | Trim |
| 14 | INSM | Insmed INC | — | NEW | New buy |
| 15 | GENB | Generate Biomedicines INC | — | NEW | New buy |
| 16 | CGON | Cg Oncology INC | — | EXIT | Sold out |
| 17 | PRCT | Procept Biorobotics CORP | — | NEW | New buy |
| 18 | GPCR | Structure Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001946237
Total reported value
$364.7M
87 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002011149
Total reported value
$364.3M
112 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001905962
Total reported value
$364.8M
111 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001103887
Total reported value
$1.8B
52 stks
2026-03-31
2 of the top 5 holdings overlap, including Insmed INC
CIK 0001536411
Total reported value
$3.4B
70 stks
2026-03-31
2 of the top 5 holdings overlap, including Natera INC
CIK 0001599882
Total reported value
$810.5M
86 stks
2026-03-31
2 of the top 5 holdings overlap, including Regeneron Pharmaceuticals